NewsBenzingaGSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est Benzinga 2026.10.28 07:58 (GMT+0) Open on Benzinga Other news Binance Alpha Opens Second Wave of Unitas (UP) Airdrop: 244 Points Can Claim 197 UP TV’s Nick and Vanessa Lachey cut price of Southern California home to $7.6 million Cheesecake Factory: Massive Traffic Burst Can't Be Ignored (NASDAQ:CAKE) HongShan and Unitree to Launch "ShanYu Chuang Plan," Focusing on Early-Stage Investment in Physical AI and Other Fields Nvidia: Risk Building, Earnings Revisions Can Turn Negative (NASDAQ:NVDA) MP Materials: Incoming Earnings And Policy Risk Make It A Sell (NYSE:MP)
HongShan and Unitree to Launch "ShanYu Chuang Plan," Focusing on Early-Stage Investment in Physical AI and Other Fields
